Evidence map›Paper›PMID 31801560›Full record

ReviewWorld journal of surgical oncology2019

Endometrioid adenocarcinoma of the rectovaginal septum with invasion of the rectum: a case report and review of literature.

Hua Yang, Jiao-Jiao Gu, Yue Qi, Wei Zhao, Xin-Lu Wang

Open access · goldAbstract readCase ReportsReview
In one paragraph

Review in World journal of surgical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Hua YangDepartment of Ultrasound, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, Republic of China.
Jiao-Jiao GuDepartment of Ultrasound, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, Republic of China.
Yue QiDepartment of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, Republic of China.
Wei ZhaoDepartment of Pathology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, Republic of China.
Xin-Lu WangDepartment of Ultrasound, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, Republic of China. wangxl1@sj-hospital.org.
China Medical University · CN

Funding

the National Natural Science Foundation of China (NSFC) No. 81501496)
6 · The paper itself

Abstract

backgroundMalignant transformation of endometriosis in the rectovaginal septum is rare and usually misdiagnosed as a colorectal or gynecological tumor. We report a rare case of primary endometrioid adenocarcinoma of the rectovaginal septum with invasion of the rectum. CASE PRESENTATION: A 57-year-old overweight woman presented with vaginal bleeding and self-reported left lower abdominal pain during the previous 2 weeks. Preoperative imaging showed a large pelvic mass with invasion of the rectum, suggestive of a gynecologic malignancy. Multiple endoscopic biopsies and immunohistochemical analyses of specimens was performed. The patient received joint gynecological-surgical laparotomy, and there were no intra- or postoperative complications. The histopathological diagnosis was rectovaginal endometrioid adenocarcinoma with rectum infiltration. The patient received adjuvant chemotherapy and achieved good treatment response, with no early complications. At 12 months after surgery, there was no evidence of recurrence.

conclusionsA high index of clinical suspicion is required for the diagnosis of endometrioid adenocarcinoma in the rectovaginal septum. Surgery combined with additional chemotherapy or radiotherapy seems to be a standard treatment, and hormonal therapy is optional. The efficacies of other therapies, including targeted medication and immunotherapy, are unknown.

Indexed as

AdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, EndometrioidCombined Modality TherapyEndometrial NeoplasmsFemaleGynecologic Surgical ProceduresHumansMiddle AgedNeoplasm InvasivenessPrognosisRectal NeoplasmsVaginal NeoplasmsDiagnosisEndometrioid adenocarcinomaEndometriosisMalignant transformationRectovaginal

Identifiers

PMID31801560
PMCPMC6894269
OpenAlexW2991933747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.